Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
FiercePharma12d
Novo Nordisk expands Ozempic's turf with new FDA nod to curb kidney disease risks
When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...
GlobalData on MSN11d
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
Novo Nordisk is eyeing up further indications for its blockbuster drug such as a potential treatment for metabolic ...
EurekAlert!13d
Study shows promise for treating core symptom of frontotemporal dementia
A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...
Crikey10h
The company behind Ozempic is turning weight loss into massive profits
Novo Nordisk boasts 45 million customers using its drug, which has caused a revolution in weight-loss treatment. But competitors are nipping at its heels.
The Financial Express12d
USFDA gives nod to Novo Nordisk’s Ozempic to reduce risk of kidney failure
Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...
Morningstar5d
Novo Nordisk's Innovation Supports a Wide Moat and GLP-1 Market Growth
Novo Nordisk accounts for 34% of the global diabetes ... fatty liver disease, sleep apnea, and Alzheimer's, and Novo and Lilly are running phase 3 trials of semaglutide and tirzepatide in many ...